Latest Breaking News On - Christopher delorefice - Page 1 : comparemela.com

Becton, Dickinson and Company (NYSE:BDX) Q1 2024 Earnings Call Transcript

Becton, Dickinson and Company (NYSE:BDX) Q1 2024 Earnings Call Transcript February 1, 2024 Becton, Dickinson and Company beats earnings expectations. Reported EPS is $2.68, expectations were $2.39. Becton, Dickinson and Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome […]

United statesChristopher deloreficeBd life sciencesGrowth in medication delivery solutionsSoftware engineersCatheter solutionsLatin americaInfusion systemPharmacy automationPharmaceutical systemsMedication delivery solutionsVascular access managementClinical reagentsRotarex atherectomy systemStress high paying jobs in the worldBest software

How the incoming governor can restore public trust in the Health Department

Plus: H+H to extend affiliation deal with SUNY Downstate for up to $24.7M Jewish Board files layoff notice for Bronx, Westchester locations Brooklyn menopause telehealth startup raises $3.8M seed round

New yorkUnited statesEast flatbushNew jerseyLong islandKings countyWestchester countyConey islandFranklin lakesConey island hospitalMachelle allenAlexis ohanianPat kaneGuy razAlessandra hendersonMaya kaufman

J&J s DelOrefice to join BD as CFO

BD (Becton, Dickinson and Co.) said Christopher DelOrefice was named executive vice president and chief financial officer, effective Sept. 6.

United statesChristopher deloreficeTom polenChristopher reidyBd technology global servicesFilms incAstra zeneca pharmaceuticalsAmerica business developmentAmetek incFranklin lakes basedMedical devicesCorporate mergersPharmaceutical north america business developmentCommercial contracting financeExecutive officer presidentChairman tom

Janssen Submits New Drug Application to U S FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Janssen Submits New Drug Application to U S FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United kingdomJennifer mcintyreLee pasqualoniChristopher deloreficeSarah freemanNone of the janssen pharmaceutical companiesJanssen pharmaceuticals incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnsonJames listGlobal therapeutic area headJanssen researchJanssen pharmaceuticals

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed

GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI.

United statesNoord brabantNoord hollandCraig tendlerNoah reymondJennifer mcintyreChristopher deloreficeObinutuzumab clbEdmond chanArnon katerGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyEuropean hematology associationJanssen research developmentJanssen pharmaceutical companies